Frank Pétavy

European Medicines Agency — Netherlands

Economics, Econometrics and Finance · Social Sciences

21h-index1.5kcitations47works6.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Health Systems, Economic Evaluations, Quality of Life(17), Advanced Causal Inference Techniques(12), Statistical Methods in Clinical Trials(11), Parathyroid Disorders and Treatments(8), Pharmaceutical Economics and Policy(5)

Publications47 total

A Fast Path from Innovation to Safe and Effective Medicines
Clinical Pharmacology & Therapeutics·2025Open Access
Clinical Evidence 2030
Clinical Pharmacology & Therapeutics·2025· 18 citedOpen Access
Possible Data-Generating Models of Longitudinal Continuous Outcomes and Intercurrent Events to Investigate Estimands
Statistics in Biopharmaceutical Research·2024Open Access
Estimation of treatment effects in short‐term depression studies. An evaluation based on the <scp>ICH E9</scp>(<scp>R1</scp>) estimands framework
Pharmaceutical Statistics·2022· 16 citedOpen Access
A Simulation Study on the Estimation of the Effect in the Hypothetical Scenario of No Use of Symptomatic Treatment in Trials for Disease-Modifying Agents for Alzheimer’s Disease
Statistics in Biopharmaceutical Research·2022· 11 citedOpen Access
The Impact of COVID‐19 on the Initiation of Clinical Trials in Europe and the United States
Clinical Pharmacology & Therapeutics·2022· 33 citedOpen Access
Use of Clinical Data Interchange Standards Consortium (CDISC) Standards for Real-world Data: Expert Perspectives From a Qualitative Delphi Survey
JMIR Medical Informatics·2021· 60 citedOpen Access
Use of Clinical Data Interchange Standards Consortium (CDISC) Standards for Real-world Data: Expert Perspectives From a Qualitative Delphi Survey (Preprint)
2021· 1 citedOpen Access
The Use of a Variable Representing Compliance Improves Accuracy of Estimation of the Effect of Treatment Allocation Regardless of Discontinuation in Trials with Incomplete Follow-up
Figshare·2021Open Access
A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?
Trials·2020· 28 citedOpen Access
FAIR data sharing: The roles of common data elements and harmonization
Journal of Biomedical Informatics·2020· 162 cited
Rethinking the intention-to-treat principle: one size does not fit all
Journal of Clinical Epidemiology·2020· 6 cited
EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma
The Oncologist·2020· 57 citedOpen Access
The Use of a Variable Representing Compliance Improves Accuracy of Estimation of the Effect of Treatment Allocation Regardless of Discontinuation in Trials with Incomplete Follow-up
Statistics in Biopharmaceutical Research·2020· 20 citedOpen Access
Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials
Clinical Pharmacology & Therapeutics·2020· 84 cited
The use of a variable representing compliance improves accuracy of estimation of the effect of treatment allocation regardless of discontinuation in trials with incomplete follow-up
Figshare·2020Open Access
The Use of a Variable Representing Compliance Improves Accuracy of Estimation of the Effect of Treatment Allocation Regardless of Discontinuation in Trials with Incomplete Follow-up
Figshare·2020Open Access
Beyond “Intent‐to‐treat” and “Per protocol”: Improving assessment of treatment effects in clinical trials through the specification of an estimand
British Journal of Clinical Pharmacology·2019· 21 citedOpen Access
Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation
Clinical Pharmacology & Therapeutics·2019· 66 citedOpen Access
The changing landscape of data monitoring committees—Perspectives from regulators, members, and sponsors
Biometrical Journal·2018· 8 cited
page 1 of 3Next →

Frequent Co-authors

Lorenzo Guizzaro(8), Guido Rasi(7), Kit C. B. Roes(6), Spiros Vamvakas(6), Steven Teerenstra(5), Ciro Gallo(5), Hans‐Georg Eichler(4), Francesco Pignatti(4), Pauline T. Lukey(4), C McClinton(4), Peter C. Taylor(4), Marian Mitroiu(4), Katrien Oude Rengerink(4), Robin Ristl(4), Olivier Collignon(3), Anja Schiel(3), Peter Arlett(3), William G. Goodman(3), Maureen Reiner(3), Giovanni Tafuri(3)